Depoxythilone - Beijing Biostar Technologies

Drug Profile

Depoxythilone - Beijing Biostar Technologies

Alternative Names: UTD-1; Utidelone - Beijing Biostar Technologies

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Biostar Technologies
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase III trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 03 Apr 2017 Depoxythilone is still in phase III trials for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT02253459)
  • 08 Aug 2014 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV) (NCT02253459; ChiCTR-TRC14005100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top